XML 31 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information

15. Segment Information

The Company operates under one reportable business segment to advance the development, manufacturing and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The determination of a single reportable business segment is consistent with the consolidated financial information regularly provided to the Company’s CODM. All of the Company's long-term assets and operations are located in the United States, and the measure of segment assets is reported on the condensed consolidated balance sheets as total assets. The Company’s CODM is its Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance, including comparing actual results to budgets and forecasts to assess variances, identify trends, and guide strategic planning.

In addition to the significant expense categories included within the consolidated statements of operations, the below disaggregated amounts comprise significant research and development and general and administrative expenses. These expenses consist of (1) clinical, manufacturing and research contracts for research and development programs, (2) personnel-related expenses, including salaries, benefits and stock-based compensation, (3) professional fees, including third-party costs for goods and services such as lab supplies and contract research, and legal and other professional expenses, and (4) facility and other overhead expenses, including depreciation, occupancy, travel, insurance and other costs. Depreciation and amortization expense is consistent with those presented in the condensed consolidated statements of cash flows.

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

(in thousands)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Research and development

 

 

 

 

 

 

 

 

 

 

 

 

  Clinical, development and licensing expenses

 

$

1,362

 

 

$

873

 

 

$

2,698

 

 

$

3,548

 

  Personnel related expenses

 

 

434

 

 

 

806

 

 

 

1,316

 

 

 

2,435

 

  Professional fees

 

 

391

 

 

 

830

 

 

 

737

 

 

 

1,412

 

  Facility and other overhead expenses

 

 

249

 

 

 

349

 

 

 

687

 

 

 

999

 

     Total research and development

 

 

2,436

 

 

 

2,858

 

 

 

5,438

 

 

 

8,394

 

General and administrative

 

 

 

 

 

 

 

 

 

 

 

 

  Personnel related expenses

 

 

1,309

 

 

 

705

 

 

 

3,256

 

 

 

2,052

 

  Professional fees

 

 

1,744

 

 

 

1,281

 

 

 

3,748

 

 

 

3,585

 

  Facility and other overhead expenses

 

 

390

 

 

 

411

 

 

 

960

 

 

 

1,176

 

     Total general and administrative

 

$

3,443

 

 

$

2,397

 

 

$

7,964

 

 

$

6,813